PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer, and Karen Andreas, M.S. as Vice President of Clinical Operations. These appointments come as the company advances its product candidates, CTIM-76 and CT-95, into Phase 1 clinical trials.
Strategic Leadership Additions:
Dr. Dansky Ullmann brings over 30 years of experience in oncology therapeutics development. He was previously the CMO at Avenge Bio and MaxCyte, and has held senior roles at Infinity Pharmaceuticals, Takeda Pharmaceuticals, and the National Cancer Institute. His extensive background includes guiding the clinical advancement of various therapies, including FDA-approved Copiktra®.
Ms. Andreas has nearly 20 years of experience in clinical operations within oncology. She was recently Vice President of Clinical Operations at Avenge Bio and has held significant roles at Boston Pharmaceuticals, Merrimack Pharmaceuticals, and ArQule. She has successfully led clinical operations and program management for multiple oncology assets.
“We are thrilled to welcome Dr. Dansky Ullmann and Ms. Andreas to our team at this exciting time as the Company advances its product candidates,” said Martin Lehr, CEO of Context. “Their expertise in oncology and T cell therapies will be invaluable as we move our programs forward.”
Inducement Grants and Future Hires:
In connection with Dr. Dansky Ullmann’s hiring, the company will grant him a stock option award for 202,170 shares, effective August 1, 2024. Additionally, new hires joining on August 1 and August 12, 2024, will receive stock option awards totaling 115,237 shares.
Accelerating Clinical Development & Strengthening Team
Shareholders should note the strategic significance of these leadership additions. Dr. Dansky Ullmann and Ms. Andreas bring a wealth of experience that could accelerate the clinical development of Context’s pipeline. Their track records in successfully advancing oncology programs provide a strong foundation for the company’s future growth.
The inducement grants and new hires also signal Context’s commitment to strengthening its team as it embarks on critical clinical trials. These steps could enhance the company’s capabilities and improve its operational efficiency.
Context Therapeutics’ latest appointments and strategic moves highlight its focus on advancing its clinical-stage assets and strengthening its leadership team. With seasoned professionals like Dr. Dansky Ullmann and Ms. Andreas on board, the company is well-positioned to navigate the complexities of clinical development and potentially deliver breakthrough therapies in oncology.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.